PIPELINE

Targeting What Others Won't, Advancing What Others Can't

VivaMed BioPharma’s pipeline includes over 50 active drug assets—ranging from new chemical entities to repurposed drugs—focused on areas of critical unmet need. We prioritize conditions with high clinical urgency, limited treatment options, and strong scientific rationale. Our AI-powered development model helps us identify promising opportunities earlier and accelerate them through the pipeline with less risk, lower cost, and faster timelines.

THERAPEUTIC AREAS

Focused Where Impact Is Most Urgent

We develop therapies across five high-priority categories—each chosen for its clinical relevance, unmet need, and potential for scalable innovation.

Disclaimer: The information presented on this page is for general informational purposes only. It does not constitute medical advice, clinical guidance, or a recommendation regarding any treatment, diagnostic, or therapeutic decision. Patients and caregivers should always seek the advice of a qualified healthcare professional with any questions regarding a medical condition or treatment. References to development status, timelines, or outcomes are forward-looking and subject to significant risks and uncertainties.

DEVELOPMENT STRATEGY

A Smarter, Faster Pipeline Model

Unlike traditional pipelines that rely on a single asset, our model diversifies risk by developing multiple compounds across therapeutic areas and stages. We accelerate development using AI to model toxicity, optimize dosage, and draft regulatory and IP filings. We also prioritize repurposed drugs and novel formulations—leveraging existing safety data to cut time and cost from development timelines.

  • 50+ active drug assets in development
  • 150+ licensed or developed to date
  • 39 regulatory approvals supported
  • AI-assisted development, from ideation to IND
  • Pipeline includes both breakthrough therapies and best-in-class repurposed drugs
About Us

CONTACT

Let's Connect

Have a question, opportunity, or idea? Whether you’re a researcher, investor, or potential partner—we’d love to hear from you.